Table II.
Characteristics of the Three (Single, Multiple, and Delayed) TPE Cohorts
| TPE Cohorts | |||
|---|---|---|---|
| Single TPE (N = 40) | Multiple TPE (N = 42) | Delayed TPE (N = 27) | |
| N (%) | N (%) | N (%) | |
|
| |||
| *Time from transplant (days) | |||
| Mean | 0 | 0 | 300 |
| Median (Q1, Q3) | 245 (9, 517) | ||
| Range | 2 - 1368 | ||
|
| |||
| Age (mean, SD) | 51, 16 | 50, 18 | 42, 22 |
|
| |||
| Pediatric (Age < 18) | 2 (5) | 3 (7) | 6 (22) |
|
| |||
| Sex | |||
| Male | 28 (70) | 16 (38) | 15 (56) |
| Female | 12 (30) | 26 (62) | 12 (44) |
|
| |||
| Race | |||
| Other | 1 (3) | 2 (5) | 2 (7) |
| Black/African American | 12 (30) | 25 (59) | 11 (41) |
| White/Caucasian | 27 (67) | 15 (36) | 14 (52) |
|
| |||
| Transplant Indication | |||
| Non-ischemic cardiomyopathy | 18 (45) | 26 (62) | 14 (52) |
| Ischemic cardiomyopathy | 17 (43) | 10 (24) | 7 (26) |
| Congenital heart defect | 1 (2) | 5 (12) | 6 (22) |
| Other | 4 (10) | 1 (2) | 0 (0) |
|
| |||
| TPE Indication | |||
| Graft dysfunction and/or AMR | 0 (0) | 7 (17) | 27 (100) |
| +PRA, +HLA Ab | 27 (68) | 8 (19) | 0 (0) |
| +Xmatch | 0 (0) | 26 (62) | 0 (0) |
| Other | 13 (32) | 1 (2) | 0 (0) |
|
| |||
| Medications | |||
| Steroids | 40 (100) | 42 (100) | 27 (100) |
| Monoclonal antibody | 39 (98) | 39 (93) | 6 (22) |
| Immune globulin | 1 (3) | 11 (26) | 16 (59) |
| Standard immunosuppression | 22 (55) | 42 (100) | 27 (100) |
|
| |||
| Post-transplant infection | 16 (40) | 17 (40) | 9 (33) |
*
Time from transplant is measured in days. TPE = Therapeutic plasma exchange; N = Number; Q1 = First Quartile; Q3 = Third Quartile; SD = Standard deviation; +PRA = positive panel reactive antibodies; +HLA Ab = positive human leukocyte antigen antibodies; AMR = antibody-mediated rejection.